International Journal of Cancer · 2016 · 179 citations · 29 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaTumor MicroenvironmentCancer Cell SignalingCancer Molecular PathologyCellular Responses To HypoxiaKidney CancerRenal Cell CarcinomaTumor Suppressor GenesHypoxia-inducible Factor ActivationHypoxia-inducible Factor RegulationHypoxia-inducible Factor SignalingHypoxia-inducible RegulationHypoxia-inducible SignalingPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayTumor Microenvironment Hypoxia
In our study, we demonstrate that ccRCC cell lines with impaired function of pVHL to degrade HIFα express elevated levels of PD-L1. In vitro analysis provided evidence that both reconstitution of pVHL and silencing of HIF2α, but not of HIF1α, lead to reduced PD-L1 expression. The strong correlation of expression between the HIF2α-specific HIF target Glut1 and PD-L1 confirmed this finding in ccRCC cell lines and tissue. Soluble PD-L1 levels remained constant in the sera of ccRCC patients regardless of the PD-L1 expression status in their tumors. In conclusion, our data suggest PD-L1 as HIF2α target, which is upregulated in pVHL deficient ccRCC. The combination of PD-L1 targeting drugs with HIF inhibiting agents may be an additional option for the treatment of ccRCC.
29
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Integrated molecular analysis of clear-cell renal cell carcinoma
Yusuke Sato, Tetsuichi Yoshizato, Yuichi Shiraishi et al. · Nature Genetics · 2013 · 1.3K citations